liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta
Karolinska Institute.
Linköping University, Department of Clinical and Experimental Medicine, Clinical Chemistry. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Laboratory Medicine, Department of Clinical Chemistry.
Karolinska University Hospital.
Karolinska Institute.
2010 (English)In: ACTA PAEDIATRICA, ISSN 0803-5253, Vol. 99, no 12, 1834-1840 p.Article in journal (Refereed) Published
Abstract [en]

Aim: To assess the role of biochemical bone markers in classification of children with osteogenesis imperfecta (OI), their possible association with vertebral compression fractures in milder forms of OI and their role in monitoring of intravenous pamidronate (APD) treatment. Methods: Serum total alkaline phosphatase (ALP), bone ALP isoforms (in a subgroup), osteocalcin, type I procollagen carboxy-terminal propeptide, carboxy-terminal telopeptide of type I collagen, and urine deoxypyridinoline (DPD) were measured in a cross-sectional study of 130 untreated individuals, 0.25-20.9 years (median 6.7), with OI types I, III and IV. Of those, sixty-nine were also assessed longitudinally during monthly APD treatment. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. Results: Significant differences in bone markers, however not sufficient for individual clinical use, were found in the larger untreated group but not between subgroups with or without vertebral compressions. All bone markers decreased during treatment for 1.0-12.5 years, but with different relative amounts. Changes were not correlated to the improvement in BMD, mobility or pain. Conclusion: Bone markers are, despite significant differences, not useful for the classification of OI type in the individual child and are not associated with vertebral compressions. Serum ALP and urinary DPD are sensitive in monitoring bisphosphonate treatment.

Place, publisher, year, edition, pages
Blackwell Publishing Ltd , 2010. Vol. 99, no 12, 1834-1840 p.
Keyword [en]
Bisphosphonate, Bone metabolism markers, Bone turnover, Osteogenesis imperfecta, Paediatric
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-63161DOI: 10.1111/j.1651-2227.2010.01968.xISI: 000283690300019OAI: diva2:376657
Available from: 2010-12-13 Created: 2010-12-13 Last updated: 2010-12-13

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Magnusson, Per
By organisation
Clinical ChemistryFaculty of Health SciencesDepartment of Clinical Chemistry
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 60 hits
ReferencesLink to record
Permanent link

Direct link